About RepliCel

Overview

RepliCel is a regenerative medicine company focused on aesthetics and orthopedics. Our cell therapy products are tailor-made to restore cellular function to rejuvenate aging or sun-damaged skin, regrow hair, and repair tendons. Our next-generation dermal injection technology is designed to improve the control and precision of aesthetic treatments. RepliCel is dedicated to improving everyday lives.

Technology

RepliCel is developing several products from two unique cell populations, both taken from the hair follicles embedded in a small skin biopsy taken from the back of a patient's head.

RepliCel is also developing a medical device based on several patent-protected technologies related to improving patient injections.

Products

RepliCel is developing the following products:

RCH-01 – Cell therapy for pattern baldness
RCS-01 – Cell therapy for aging or sun-damaged skin
RCT-01 – Cell therapy for tendon degeneration
DermaPrecise™ – Next-generation dermal injection device

RepliCel has a management team and board of directors with a longstanding commitment to the Company and its technologies. RepliCel’s co-founders, Kevin McElwee and Rolf Hoffmann, continue to contribute to the Company’s science and strategy, supported by clinical advisors in Europe, North America and Asia.

The Company also works with a network of third-party collaborators.

Management

Andrew Schutte

President & CEO

Andrew Schutte

President & CEO

Andrew Schutte is President and Chief Executive Officer of RepliCel and a member of its Board of Directors. He has spent his career in entrepreneurial businesses, building early-stage companies from the ground up. As CEO, he led RepliCel’s transition from a publicly traded company to a privately held one, and he oversees the Company’s strategy, operations and research and development programs. Mr. Schutte has been a shareholder of RepliCel since 2017 and joined its Board of Directors in 2018.

Ben Austring

Chief Operating Officer

Ben Austring

Chief Operating Officer

Mr. Austring is RepliCel's Chief Operating Officer, responsible for the company's operations and development. He has a law degree, and brings experience in Health Canada regulatory matters. His experience spans drug distribution, supply chain management, and strategic partnerships.

Dr. Kevin McElwee, PhD

Chief Scientific Officer

Dr. Kevin McElwee, PhD

Chief Scientific Officer

Dr. McElwee, co-discoverer of the Company's technology and co-founder of RepliCel, is Professor of Biomedical Sciences at the University of Bradford’s School of Chemistry and Biosciences. Previously, he was an Associate Professor in the Department of Dermatology and Skin Health at the University of British Columbia, and Director of the Hair Research Laboratory in the Vancouver Coastal Health Research Institute at Vancouver General Hospital (VGH). His research has been funded by competitive grants awarded by multiple organizations including the Canadian Institutes for Health Research (the equivalent of the National Institutes for Health in the USA).

Dr. McElwee is one of only a small group of research scientists worldwide who study hair biology and associated diseases. He has worked as a hair research scientist for many years and has published over 70 medical journal articles, research abstracts and academic book chapters on hair loss research. Dr. McElwee received his Bachelor of Science degree from the University of Aberdeen, Scotland and his PhD from the University of Dundee, Scotland. Postdoctoral training included three years at the Jackson Laboratory in Maine and four years at the University of Marburg, Germany, studying various hair loss diseases.

Dr. McElwee serves as RepliCel’s Chief Scientific Officer.

David Kwok, CPA

Chief Financial Officer

David Kwok, CPA

Chief Financial Officer

Mr. Kwok is a Chartered Professional Accountant and has extensive experience with private and public companies. He qualified as a Chartered Accountant in 2008.

Board of Directors

David Hall

Chairman of the Board

David Hall

Chairman of the Board

Mr. Hall served as CEO and President of RepliCel Life Sciences from 2012 through 2015. He helped diversify RepliCel’s cell therapy programs from a single program to three current clinical programs, as well as the development of the DermaPrecise™ dermal injector. Previously, Mr. Hall consulted to government, pharma industry, biotech, eHealth and NGOs for two years. For the prior 15 years, Mr. Hall served in multiple roles including as the CFO, CCO, Treasurer and Secretary of Angiotech Pharmaceuticals Inc.

Mr. Hall is a Past Chair and board member of Life Sciences BC and current director of Providence Health Care Research Institute and VANC Pharmaceuticals. He is the author of Life Sciences BC’s position papers for the Premier’s Competition Council Report and Conversation on Health. Mr. Hall was also a member of the BC Task Force on PharmaCare and serves on the board of directors of Advantage BC. Mr. Hall holds an Honours degree in Economics and Finance from the University of Manitoba.

Mr. Hall serves as the Chairman of RepliCel’s Board of Directors.

Peter Lewis, CA

Director

Peter Lewis, CA

Director

Mr. Lewis is a chartered accountant and partner with Lewis and Company, a firm specializing in taxation law since 1993. His areas of expertise include tax planning, acquisitions and divestitures, reorganizations and estate planning. Mr. Lewis is a sought-after educator, having taught and presented taxation courses at the Institute of Chartered Accountants of British Columbia and the Canadian Tax Foundation.

He served on the Taxation Committee of the Institute of Chartered Accountants for three years and as President and Secretary-Treasurer at the Jericho Tennis Club for a combined ten years. Mr. Lewis is currently a member of the University Endowment Lands Community Advisory Committee.

Mr. Lewis is a shareholder in RepliCel and serves as a member of the Board of Directors.

Andrew Schutte

Director, President & CEO

Andrew Schutte

Director, President & CEO

Mr. Schutte is RepliCel’s President and Chief Executive Officer. His biography appears under Management.